<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2007-05-16" updated="2020-01-02">
  <drugbank-id primary="true">DB01272</drugbank-id>
  <name>Alglucosidase alfa</name>
  <description>Aglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes. It is encoded by the most predominant of nine observed haplotypes of this gene. Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen. Structurally, Alglucosidase alfa is a glycoprotein with a calculated mass of 98,008 daltons for the 883 residue mature polypeptide chain, and a total mass of approximately 109,000 daltons, including carbohydrates. It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.</description>
  <cas-number>420784-05-0</cas-number>
  <unii>DTI67O9503</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A2308</ref-id>
        <pubmed-id>17151339</pubmed-id>
        <citation>Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE: Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007 Jan 9;68(2):99-109. Epub 2006 Dec 6.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.</indication>
  <pharmacodynamics>Pompe disease (glycogen storage disease type II, GSD II, glycogenosis type II, acid maltase deficiency) is an inherited disorder of glycogen metabolism caused by the absence or marked deficiency of the lysosomal enzyme GAA. In the infantile-onset form, Pompe disease results in intralysosomal accumulation of glycogen in various tissues, particularly cardiac and skeletal muscles, and hepatic tissues, leading to the development of cardiomyopathy, progressive muscle weakness, and impairment of respiratory function. In the juvenile- and adult-onset forms, intralysosomal accumulation of glycogen is limited primarily to skeletal muscle, resulting in progressive muscle weakness. Death in all forms is usually related to respiratory failure. Alglucosidase alfa provides an exogenous source of GAA. Binding to mannose-6-phosphate receptors on the cell surface has been shown to occur via carbohydrate groups on the GAA molecule, after which it is internalized and transported into lysosomes, where it undergoes proteolytic cleavage that results in increased enzymatic activity. It then exerts enzymatic activity in cleaving glycogen.</pharmacodynamics>
  <mechanism-of-action>Alglucosidase alfa is designed to act as an exogenous source of GAA, acting to correct GAA deficiency that is the hallmark of Pompe disease. Alglucosidase alfa binds to mannose-6-phosphate receptors on the cell surface via carbohydrate groups on the GAA molecule, after which it is internalized and transported into lysosomes, where it undergoes proteolytic cleavage that results in increased enzymatic activity. It then exerts enzymatic activity in cleaving glycogen. Specifically, it hydrolyses alpha-1,4-glucose bonds.&#13;
&#13;
</mechanism-of-action>
  <toxicity>There have been no reports of overdose with alglucosidase alfa.</toxicity>
  <metabolism/>
  <absorption/>
  <half-life>2.3 &amp;plusmn; 0.4 hours.</half-life>
  <protein-binding/>
  <route-of-elimination>Via kidney and liver</route-of-elimination>
  <volume-of-distribution>* 96 ± 16 mL/kg [20 mg/kg dose]&#13;
* 119 ± 28 mL/kg [40 mg/kg dose]</volume-of-distribution>
  <clearance>* 25+/- 4 mL/hr/kg [4-hour IV infusion of 20 mg/kg]</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Acid maltase</synonym>
    <synonym language="english" coder="">Acid-alpha glucosidase</synonym>
    <synonym language="english" coder="">Aglucosidase alfa</synonym>
    <synonym language="english" coder="">Aglucosidase alpha</synonym>
    <synonym language="spanish" coder="">Alglucosidasa alfa</synonym>
    <synonym language="english" coder="">alpha-1,4-glucosidase</synonym>
    <synonym language="english" coder="">Alpha-glucosidase</synonym>
    <synonym language="english" coder="">Lysosomal Alpha-Glucosidase</synonym>
  </synonyms>
  <products>
    <product>
      <name>Lumizyme</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-0160</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-05-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125291</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myozyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000636</ema-product-code>
      <ema-ma-number>EU/1/06/333/001</ema-ma-number>
      <started-marketing-on>2006-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Myozyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000636</ema-product-code>
      <ema-ma-number>EU/1/06/333/002</ema-ma-number>
      <started-marketing-on>2006-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Myozyme</name>
      <labeller>Genzyme Europe Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000636</ema-product-code>
      <ema-ma-number>EU/1/06/333/003</ema-ma-number>
      <started-marketing-on>2006-03-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Myozyme</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-0150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-19</started-marketing-on>
      <ended-marketing-on>2018-05-24</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>5 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125141</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myozyme</name>
      <labeller>Sanofi Genzyme, a Division of Sanofi Aventis Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02284863</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>50 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Myozyme</name>
      <ingredients>Alglucosidase alfa</ingredients>
    </mixture>
    <mixture>
      <name>Myozyme</name>
      <ingredients>Alglucosidase alfa</ingredients>
    </mixture>
    <mixture>
      <name>Myozyme</name>
      <ingredients>Alglucosidase alfa</ingredients>
    </mixture>
    <mixture>
      <name>Myozyme</name>
      <ingredients>Alglucosidase alfa</ingredients>
    </mixture>
    <mixture>
      <name>Lumizyme</name>
      <ingredients>Alglucosidase alfa</ingredients>
    </mixture>
    <mixture>
      <name>Myozyme</name>
      <ingredients>Alglucosidase alfa</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Genzyme Inc.</name>
      <url>http://www.genzyme.ca</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Myozyme 50 mg vial</description>
      <cost currency="USD">720.0</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>alpha-Glucosidases</category>
      <mesh-id>D000520</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Glucosidases</category>
      <mesh-id>D005959</mesh-id>
    </category>
    <category>
      <category>Glycogen Storage Disease Type II</category>
      <mesh-id>D006009</mesh-id>
    </category>
    <category>
      <category>Glycoside Hydrolases</category>
      <mesh-id>D006026</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Hydrolytic Lysosomal Glycogen-specific Enzyme</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A16AB07">
      <level code="A16AB">Enzymes</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>44:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01272.pdf?1265922815</fda-label>
  <patents>
    <patent>
      <number>2416492</number>
      <country>Canada</country>
      <approved>2008-04-29</approved>
      <expires>2021-07-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;Alglucosidase alfa
AHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFF
PPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANR
RYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLS
TSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHG
VFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGL
GFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQ
ELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPD
FTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVG
GTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRY
AGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYP
FMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFL
EFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPVEALGSLPPP
PAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTK
GGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGV
ATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>105270.802</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C4435H6739N1175O1279S32</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>19883</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46504595</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03207</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164754753</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001289</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Alglucosidase_alfa</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201824</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/myozyme.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/alglucosidase-alfa.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004494</id>
      <name>Cation-dependent mannose-6-phosphate receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A13692</ref-id>
            <pubmed-id>17927214</pubmed-id>
            <citation>Chavez CA, Bohnsack RN, Kudo M, Gotschall RR, Canfield WM, Dahms NM: Domain 5 of the cation-independent mannose 6-phosphate receptor preferentially binds phosphodiesters (mannose 6-phosphate N-acetylglucosamine ester). Biochemistry. 2007 Nov 6;46(44):12604-17. Epub 2007 Oct 10.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P20645" source="Swiss-Prot">
        <name>Cation-dependent mannose-6-phosphate receptor</name>
        <general-function>Transmembrane signaling receptor activity</general-function>
        <specific-function>Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex.</specific-function>
        <gene-name>M6PR</gene-name>
        <locus/>
        <cellular-location>Lysosome membrane</cellular-location>
        <transmembrane-regions>186-210</transmembrane-regions>
        <signal-regions>1-26</signal-regions>
        <theoretical-pi/>
        <molecular-weight>30993.06</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6752</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P20645</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MPRD_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>46 kDa mannose 6-phosphate receptor</synonym>
          <synonym>CD Man-6-P receptor</synonym>
          <synonym>MPR 46</synonym>
          <synonym>MPR46</synonym>
          <synonym>MPRD</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013144|Cation-dependent mannose-6-phosphate receptor
MFPFYSCWRTGLLLLLLAVAVRESWQTEEKTCDLVGEKGKESEKELALVKRLKPLFNKSF
ESTVGQGSDTYIYIFRVCREAGNHTSGAGLVQINKSNGKETVVGRLNETHIFNGSNWIML
IYKGGDEYDNHCGKEQRRAVVMISCNRHTLADNFNPVSEERGKVQDCFYLFEMDSSLACS
PEISHLSVGSILLVTFASLVAVYVVGGFLYQRLVVGAKGMEQFPHLAFWQDLGNLVADGC
DFVCRSKPRNVPAAYRGVGDDQLGEESEERDDHLLPM</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF02157</identifier>
            <name>Man-6-P_recep</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>late endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mannose binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>mannose transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane signaling receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endosome to lysosome transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0004831</id>
      <name>Glycogen</name>
      <organism>Humans</organism>
      <actions>
        <action>cleavage</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17135</ref-id>
            <pubmed-id>19625484</pubmed-id>
            <citation>Hu D, Kamiya Y, Totani K, Kamiya D, Kawasaki N, Yamaguchi D, Matsuo I, Matsumoto N, Ito Y, Kato K, Yamamoto K: Sugar-binding activity of the MRH domain in the ER alpha-glucosidase II beta subunit is important for efficient glucose trimming. Glycobiology. 2009 Oct;19(10):1127-35. doi: 10.1093/glycob/cwp104. Epub 2009 Jul  22.</citation>
          </article>
          <article>
            <ref-id>A17136</ref-id>
            <pubmed-id>19275898</pubmed-id>
            <citation>Christiansen C, Hachem MA, Glaring MA, Vikso-Nielsen A, Sigurskjold BW, Svensson B, Blennow A: A CBM20 low-affinity starch-binding domain from glucan, water dikinase. FEBS Lett. 2009 Apr 2;583(7):1159-63. doi: 10.1016/j.febslet.2009.02.045. Epub 2009 Mar 9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>